Alan Guerrero

Alan Guerrero has a diverse work experience in the field of biomedical research. Alan is currently serving as the Vice President of Research and Development at Kiromic Biopharma, Inc., a position they have held since March 2023. Prior to this, they were the Head of Cell Therapy at the same company from December 2021 to February 2023. Before joining Kiromic Biopharma, Inc., Alan worked at Bellicum Pharmaceuticals, Inc. as a Senior Scientist from January 2016 to November 2020. In this role, they designed and cloned constructs for chimeric antigen receptor (CAR) T cell and CAR NK cell immunotherapy, conducted in vitro and in vivo studies, and created mouse models for CAR T cell efficacy assessment.

Between 2014 and 2016, Alan worked at MD Anderson Cancer Center, first as a Postdoctoral Fellow and later as a Research Scientist. In these positions, they focused on cancer immunotherapy, expanding and phenotyping gamma delta T cells, and designing chimeric antigen receptors targeting ROR1.

Prior to that, Alan gained research experience at the National Institutes of Health as a Post-doctoral Researcher from 2011 to 2013, and at Baylor College of Medicine as both a Post-doctoral Researcher from 2010 to 2011 and a Graduate Student from 2003 to 2010.

Overall, Alan Guerrero has extensive experience in biomedical research, with a focus on cancer immunotherapy, cell therapy, and the development of chimeric antigen receptors.

Alan Guerrero completed their education in a chronological order. From 1999 to 2003, they attended The University of Texas at Austin, where they obtained a Bachelor of Science (BS) degree in Microbiology. Following that, they pursued further studies at Baylor College of Medicine from 2003 to 2010, earning a Doctor of Philosophy (Ph.D.) degree in Immunology.